Clinical trials are an extremely important component of cancer care. According to National Comprehensive Cancer Network Guidelines, "the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged." Drs. Brown and Gold actively pursues this mission. Dr. Brown is the PI (Priniciple Investigator) at Beaumont Health of many of the clinical trials offered by cooperative groups in the U.S. (NSABP, SWOG, Alliance). Drs. Brown and Gold also have access to Clinical Trials through Karmanos Cancer Institute, A National Cancer Institute Designated Cancer Center (one of two in Michigan).
Multiple clinical trials are available through the NCI (National Cancer Institute). Dr. Brown is Principle Investigator at Beaumont Hospital, Troy (Beaumont Cancer Institute) for a number of these trials. In addition the Clinical Trials offered through the Karmanos Cancer Institute, here is a list of Beaumont Health Breast Cancer related Clinical Trials available, as of January, 2020:
Registry objective: Create a database of patients, test results, and treatment decisions which may be queried to determine the potential clinical utility of the DCISionRT test in the management of DCIS, as it is broadly incorporated into clinical practice.
Primary Registry endpoint is: Understanding the difference in physician treatment recommendations for patients diagnosed with DCIS and treated with breast conserving surgery based on availability of the DCISionRT test results (biologic factors).
TME Universal Gene Study
Understand the incidence of deleterious mutations in the general breast cancer patient population and whether criteria by which patients are currently selected for testing are adequate. A total of 1000 patients will be accrued across 15 to 20 breast surgery sites and tested with Invitae’s 80-gene multi-cancer panel (participating clinicians can also select to receive STAT results upfront for up to 9 genes to aid in surgical decisions). Target accrual for each site is 50 patients (25 in-criteria and 25 out-of-criteria patients).
THIS STUDY IS CLOSED
Medneon iGAP Registry
A retrospective and prospective observational registry documenting utility, clinical impact and patient experience for individuals with cancer, at risk of cancer and unaffected family members, who obtain genetic testing.
(The ‘NEAT’ Registry) Paradigm/TME NeoAdjuvant Breast Registry
This is a prospective, observational, case-only study linking molecular genomic test or circulating tumor molecular profiles to treatment response, recurrence free survival (RFS), anddistant metastases free survival (DMFS) in patients who have been diagnosed with breastcancer and who are treated with neo-adjuvant therapy. Only patients who receive neoadjuvant therapy and molecular genomic profile testing will participate.